Cardio3 BioSciences Ups R&D Efforts After CV Stem Cell Product Clears Safety Review
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Belgian regenerative therapies company plans to enlarge its R&D and partnering efforts after a pre-planned interim review by a Data Safety Monitoring Board gave the Phase III study of lead product C-Cure a clean bill of health.
You may also be interested in...
Vagus Nerve Stimulation For Heart Failure Fails To Impress, But BioControl Not Bothered
Data from two trials of vagus nerve stimulation to treat heart failure, sponsored by Boston Scientific and Cyberonics, respectively, were not particularly positive for the future of this therapy. But another developer of a VNS system for heart failure, BioControl, says the results won’t affect its chances for approval.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.